The ROR1 pseudokinase diversifies signaling outputs in MET‐addicted cancer cells
Open Access
- 7 April 2014
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 135 (10) , 2305-2316
Abstract
MET is a master gene controlling a genetic program driving proliferation, apoptosis protection and invasion. The ROR1 pseudokinase acts as a MET substrate. However, its contribution to MET signaling and MET‐dependent biological outcomes remains to be elucidated. By structure‐function analysis of ROR1 mutants, we show that ROR1 encompasses two major substrate regions: one is located in the proline‐rich domain and is directly phosphorylated by MET; the other resides in the pseudokinase domain and is phosphorylated through intermediate activation of SRC. Differential phosphorylation of these two regions dictates the execution of specific responses: phosphorylation of the ROR1 proline‐rich domain by MET—but not phosphorylation of the pseudokinase domain by SRC—is necessary and sufficient to control MET‐driven proliferation and protection from apoptosis. Differently, both the proline‐rich and the pseudokinase domains mediate cell invasion. Consistent with the role of ROR1 in specifying the functional consequences of MET‐dependent signals, ROR1 silencing leads to selective attenuation of only some of the signal transduction pathways sustained by MET. These data enlighten the so far elusive function(s) of pseudokinases and identify a mechanism of biological diversification, based on substrate specificity of oncogenic kinases.Keywords
Funding Information
- Paolo M. Comoglio: AIRC “IG” (11852)
- AIRC “Special Program Molecular Clinical Oncology 5xMille” (9970)
- Livio Trusolino: AIRC “IG” (10116)
This publication has 48 references indexed in Scilit:
- Assessing the range of kinase autoinhibition mechanisms in the insulin receptor familyBiochemical Journal, 2012
- ROR1 and ROR2 in Human Malignancies: Potentials for Targeted TherapyFrontiers in Oncology, 2012
- Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cellsBritish Journal of Haematology, 2010
- Signal integration by JNK and p38 MAPK pathways in cancer developmentNature Reviews Cancer, 2009
- RNAi screen for rapid therapeutic target identification in leukemia patientsProceedings of the National Academy of Sciences, 2009
- The Deleted in Brachydactyly B Domain of ROR2 Is Required for Receptor Activation by Recruitment of SrcPLOS ONE, 2008
- Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5aProceedings of the National Academy of Sciences, 2008
- Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastomaProceedings of the National Academy of Sciences, 2007
- β4 integrin activates a Shp2–Src signaling pathway that sustains HGF-induced anchorage-independent growthJournal of Cell Biology, 2006
- A Signaling Adapter Function for α6β4 Integrin in the Control of HGF-Dependent Invasive GrowthCell, 2001